Barcelona becomes focus of international biotechnology investors
- Presentations of 30 Spanish projects will take place for an audience of 50 investors from Spain, the UK, Switzerland and France, among others.
- Catalonia, where the largest percentage of ASEBIO member companies are based (26%) also boasts the greatest number of biotechnology companies in Spain and the second-largest number of startups.
- ASEBIO is working to create a favourable fiscal and legal framework, academic and clinical ecosystems with dynamic R&D and technology transfer processes, and an increase in FDI to generate greater confidence among both domestic and international investors.
Madrid, 27 September 2017. The Spanish Bioindustry Association (ASEBIO), with the support of ICEX-Invest in Spain, has made Barcelona the focus of attention for both national and international investors in the biotechnology area, with the city providing the backdrop for the presentation of Spanish biotechnology to an international audience.
The first ever ASEBIO Investor Day will take place today and tomorrow at the Barcelona Science Park. The event has been organised with the support of ICEX–Invest in Spain in collaboration with Barcelona Science Park, CataloniaBio, BIOCAT and the Spanish Biotech Platform. It will bring together 50 investors and pharmaceutical companies from Spain, the UK, Switzerland, France and a number of other countries.
The initiative is made up of two parts:
- 26 September: training day organised by Johnson & Johnson for biotechnology startups that need to communicate their business plans to investors.
- 27 September: Investment forum for the 30 best proposals. The companies selected will have the opportunity to present their projects and schedule private meetings with investors.
During the opening event the President of ASEBIO, Jordi Martí, underlined that “the association, which represents the Spanish biotechnology sector as a whole, helps enterprises and investors to create new business opportunities. We are working to bring about a favourable environment for the development of the sector, particularly investment in life sciences, which is one of the biggest challenges for the development of biotech SMEs in Spain.”
For these reasons, ASEBIO is working on:
- Creating a favourable fiscal and legal framework.
- Fomenting academic and clinical ecosystems with dynamic R&D and technology transfer processes.
- Creating an atmosphere of confidence among investors by using events such as Investor Day and Biospain to build relationships between local and international investors, providing access to legal services, auditing, quality assurance etc.
Some of the investors in attendance will include Ysios Capital, Caixa Capital Risc, Inveready, Mondragón Corporación, Edmond de Rothschild, Merck Ventures, Omnix Health and Sofinnova. The following entities will present projects:
- Ability Pharma
- ADmit Therapeutics
- Allinky Biopharma
- Asparia Glycomics
- Autonomous University of Barcelona
- Biome Makers
- Lykera Biomed
- Made of Genes
- NBS Newborn Solutions
- SOM Biotech
- Vytrus Biotech
ASEBIO intends this event to consolidate the evolution of the Spanish biotechnology market into an international biotechnology hub, as well as help Spanish companies to identify sources of finance and embark on internationalisation processes.
A favourable environment
Catalonia’s Bioregion is made up of 871 different enterprises and 95 research entities, including 41 research centres, 18 university hospitals, 14 science parks hosting life sciences activities and 12 universities offering courses in life sciences, according to data provided by BIOCAT.
In 2015 there were 2,981 enterprises engaged in biotechnology related activities in Spain (+8.72% compared to 2014), of which 654 are dedicated biotechnology enterprises (+4.17%), according to data in the ASEBIO Report 2016.
The number of people directly employed by the biotechnology sector reached 182,156 (+2.35%). The turnover of dedicated biotechnology enterprises totalled €8.2 billion in 2015, with growth reaching 7.38%.
Internal spending on biotechnology R&D reached €578 million (+8.31), regaining some of the the growth lost over recent years, according to INE data for 2015.
Catalonia confirmed its position as the autonomous community with the greatest concentration of biotechnology user companies (17.3%), followed by Andalusia (14.7%) and Madrid (10.1%), according to data from the ASEBIO Report 2016.
As regards dedicated biotechnology companies, Catalonia accounts for 27.6% of the total, followed by Madrid (16.1%), Andalusia (12.3%) and Valencia (9.9%).
During 2016 a total of 43 new biotechnology enterprises were launched in Spain, with Catalonia being the location for the second-largest proportion, at nine, behind Andalusia but ahead of the Basque Country and Madrid.
70 ASEBIO members are based in Catalonia, the largest single number (26%) out of a total of 270 across Spain.
Financial operations in the biotechnology sector
En 2016, las empresas biotecnológicas españolas continuaron captando fondos internacionales en cantidades sin precedentes en España. El año pasado se llevaron a cabo 77 operaciones biotech en el país, con un volumen de inversión de 127 millones de euros, entre ampliaciones de capital privado, salidas a bolsa, emisión de acciones, operaciones corporativas, financiación complementaria y actividad del capital riesgo. Es destacable que durante el primer semestre de 2017, ya se había captado más inversión internacional que durante todo 2016, superando los 70 millones de euros hasta junio de 2017. La mayoría de estas operaciones, han sido protagonizadas por entidades socias de ASEBIO. En el primer semestre, destacan las operaciones de Medlumics, Stat Diagnóstica, Vivacell, NIMGenetics y Anaconda Biomed.
Over the course of 2016 the Spanish biotechnology sector continued to attract international investment in unprecedented quantities. Last 77 biotech operations took place in Spain, worth a total of €127 million in investments from capital expansions, IPOs, issuing new stock, corporate operations, complementary financing, and venture capital. Remarkably, just in the first quarter of 2017, international investment exceeded total investments for the entirety of 2016, with €70 million raised by June 2017. Most of these operations have involved ASEBIO members. In the first quarter significant operations included those involving Medlumics, Stat Diagnóstica, Vivacell, NIMGenetics and Anaconda Biomed.
The main sponsor for this event is Johnson&Johnson Innovation, with further sponsorship from Ysios, Bioseed, CESIF, Euronext, and the collaboration of ASCRI, BIOCAT, CataloniaBio, Barcelona Science Park and the Spanish Biotech Platform.
The hashtag for the event is #ASEBIOInvestorday
This event is part of the European Biotech Week #BiotechWeek
For further information:
Head of Communication at ASEBIO
Landline: + 34 91 2109374/10
Fax: +34 91 2500063
Mobile: + 34 663 117 293